Knut Robert Andersen

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller et al. · The Lancet Diabetes & Endocrinology · 2014 · 379 citations

Medicine, Pharmacology, Pharmacotherapy +11

Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial

Martin Ridderstråle, Julio Rosenstock, Knut Robert Andersen et al. · Diabetes Obesity and Metabolism · 2018 · 55 citations

Medicine, Pharmacology, Pharmacotherapy +17

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial

Mark A. Espeland, Richard E. Pratley, Julio Rosenstock et al. · Diabetes Obesity and Metabolism · 2020 · 30 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial

Josephine Harrington, Jacob A. Udell, W. Schuyler Jones et al. · European Journal of Heart Failure · 2023 · 21 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17